|
1
|
Buckner JC, Shaw EG, Pugh SL, Chakravarti
A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, et
al: Radiation plus procarbazine, CCNU, and vincristine in low-grade
glioma. N Engl J Med. 374:1344–1355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crane CA, Han SJ, Ahn B, Oehlke J, Kivett
V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, et al:
Individual patient-specific immunity against high-grade glioma
after vaccination with autologous tumor derived peptides bound to
the 96 KD chaperone protein. Clin Cancer Res. 19:205–214. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pan E, Yu D, Yue B, Potthast L, Chowdhary
S, Smith P and Chamberlain M: A prospective phase II
single-institution trial of sunitinib for recurrent malignant
glioma. J Neurooncol. 110:111–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li HL, Cui XL, Zhang JN and Lin S:
Chemotherapy alleviates subacute recurrent glioma-associated
refractory cerebral edema by downregulating vascular endothelial
growth factor. Med Oncol. 31:132014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo X, Zheng X and Huang H: Protective
effects of dexmedetomidine on brain function of glioma patients
undergoing craniotomy resection and its underlying mechanism. Clin
Neurol Neurosurg. 146:105–108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li P, Wang X, Shan Q, Wu Y and Wang Z:
MicroRNA-130b promotes cell migration and invasion by inhibiting
peroxisome proliferator-activated receptor-gamma in human glioma.
Oncol Lett. 13:2615–2622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu X, Chen J and Zhang J:
AdipoR1-mediated miR-3908 inhibits glioblastoma tumorigenicity
through downregulation of STAT2 associated with the AMPK/SIRT1
pathway. Oncol Rep. 37:3387–3396. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pal R and Greene S: microRNA-10b is
overexpressed and critical for cell survival and proliferation in
medulloblastoma. PLoS One. 10:e01378452015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mazurowski MA, Clark K, Czarnek NM,
Shamsesfandabadi P, Peters KB and Saha A: Radiogenomics of
lower-grade glioma: Algorithmically-assessed tumor shape is
associated with tumor genomic subtypes and patient outcomes in a
multi-institutional study with The Cancer Genome Atlas data. J
Neurooncol. 133:27–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang MH, Lin CL, Zhang JJ, Weng ZP, Hu T,
Xie Q and Zhong XY: Role of PTEN in cholera toxin-induced SWO38
glioma cell differentiation. Mol Med Rep. 7:1912–1918. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elhag R, Mazzio EA and Soliman KF: The
effect of silibinin in enhancing toxicity of temozolomide and
etoposide in p53 and PTEN-mutated resistant glioma cell lines.
Anticancer Res. 35:1263–1269. 2015.PubMed/NCBI
|
|
12
|
Lester A, Rapkins R, Nixdorf S, Khasraw M
and McDonald K: Combining PARP inhibitors with radiation therapy
for the treatment of glioblastoma: Is PTEN predictive of response?
Clin Transl Oncol. 19:273–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koul D, Wang S, Wu S, Saito N, Zheng S,
Gao F, Kaul I, Setoguchi M, Nakayama K, Koyama K, et al:
Preclinical therapeutic efficacy of a novel blood-brain
barrier-penetrant dual PI3K/mTOR inhibitor with preferential
response in PI3K/PTEN mutant glioma. Oncotarget. 8:21741–21753.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koul D, Shen R, Kim YW, Kondo Y, Lu Y,
Bankson J, Ronen SM, Kirkpatrick DL, Powis G and Yung WK: Cellular
and in vivo activity of a novel PI3K inhibitor, PX-866, against
human glioblastoma. Neuro Oncol. 12:559–569. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paul-Samojedny M, Pudelko A, Kowalczyk M,
Fila-Daniłow A, Suchanek-Raif R, Borkowska P and Kowalski J:
Combination therapy with AKT3 and PI3KCA siRNA enhances the
antitumor effect of temozolomide and carmustine in T98G
glioblastoma multiforme cells. BioDrugs. 30:129–144. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Guo L, Li Y, Feng GH, Teng F, Li
W and Zhou Q: MicroRNA-494 promotes cancer progression and targets
adenomatous polyposis coli in colorectal cancer. Mol Cancer.
17:12018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang A, Wang X, Yu C, Jin Z, Wei L, Cao J,
Wang Q, Zhang M, Zhang L, Zhang L, et al: microRNA-494 is a
potential prognostic marker and inhibits cellular proliferation,
migration and invasion by targeting SIRT1 in epithelial ovarian
cancer. Oncol Lett. 14:3177–3184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma YB, Li GX, Hu JX, Liu X and Shi BM:
Correlation of miR-494 expression with tumor progression and
patient survival in pancreatic cancer. Genet Mol Res.
14:18153–18159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ducassou A, Uro-Coste E, Verrelle P,
Filleron T, Benouaich-Amiel A, Lubrano V, Sol JC, Delisle MB, Favre
G, Ken S, et al: Alphavbeta3 integrin and fibroblast growth factor
receptor 1 (FGFR1): Prognostic factors in a phase I–II clinical
trial associating continuous administration of Tipifarnib with
radiotherapy for patients with newly diagnosed glioblastoma. Eur J
Cancer. 49:2161–2169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartels U, Wolff J, Gore L, Dunkel I,
Gilheeney S, Allen J, Goldman S, Yalon M, Packer RJ, Korones DN, et
al: Phase 2 study of safety and efficacy of nimotuzumab in
pediatric patients with progressive diffuse intrinsic pontine
glioma. Neuro Oncol. 16:1554–1559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Karremann M, Hoffmann M, Benesch M,
Kwiecien R, von Bueren AO and Kramm CM: Secondary solid
malignancies after high-grade glioma treatment in pediatric
patients. Pediatr Hematol Oncol. 32:467–473. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang C, Liu S, Yuan X, Hu Z, Li H, Wu M,
Yuan J, Zhao Z, Su J, Wang X, et al: Valproic acid promotes human
glioma U87 cells apoptosis and inhibits glycogen synthase
kinase-3beta through ERK/Akt signaling. Cell Physiol Biochem.
39:2173–2185. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Y, Dong L, Bao S, Wang M, Yun Y and Zhu
R: FK228 augmented temozolomide sensitivity in human glioma cells
by blocking PI3K/AKT/mTOR signal pathways. Biomed Pharmacother.
84:462–469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin CJ, Chen TL, Tseng YY, Wu GJ, Hsieh
MH, Lin YW and Chen RM: Honokiol induces autophagic cell death in
malignant glioma through reactive oxygen species-mediated
regulation of the p53/PI3K/Akt/mTOR signaling pathway. Toxicol Appl
Pharmacol. 304:59–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Su S, Luo, Liu X, Liu J, Peng F, Fang C
and Li B: miR-494 up-regulates the PI3K/Akt pathway via targetting
PTEN and attenuates hepatic ischemia/reperfusion injury in a rat
model. Biosci Rep. 37:2017. View Article : Google Scholar
|
|
27
|
Li XT, Wang HZ, Wu ZW, Yang TQ, Zhao ZH,
Chen GL, Xie XS, Li B, Wei YX, Huang YL, et al: miR-494-3p
regulates cellular proliferation, invasion, migration, and
apoptosis by PTEN/AKT signaling in human glioblastoma cells. Cell
Mol Neurobiol. 35:679–687. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen JH, Zhang P, Chen WD, Li DD, Wu XQ,
Deng R, Jiao L, Li X, Ji J, Feng GK, et al: ATM-mediated PTEN
phosphorylation promotes PTEN nuclear translocation and autophagy
in response to DNA-damaging agents in cancer cells. Autophagy.
11:239–252. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu H, Xie R, Liu X, Shou J, Gu W, Gu S
and Che X: MicroRNA-494 improves functional recovery and inhibits
apoptosis by modulating PTEN/AKT/mTOR pathway in rats after spinal
cord injury. Biomed Pharmacother. 92:879–887. 2017. View Article : Google Scholar : PubMed/NCBI
|
